Expanding Therapeutic Options for People with Migraine

 

Lasmiditan is the first in a new class of migraine therapies called "ditans"– agents designed specifically to act through non-vasoconstrictive mechanisms to serve the needs of different subgroups of patients, including those who have cardiovascular risk factors or stable cardiovascular disease, and those who are dissatisfied with their current therapies.

Lasmiditan MOA

Lasmiditan selectively targets 5‑HT1F receptors expressed in the trigeminal pathway without vasoconstriction.

Lasmiditan MOA Colucid

Novel Mechanism of Action

Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5‑HT1F receptors expressed in the trigeminal nerve pathway.

Lasmiditan 5‑HT1F receptor agonism

  • Highly potent
  • Highly selective

Treatments

Lasmiditan

Triptans

Primary Site of Action

Trigeminal Pathway

Blood Vessels

Receptor

5‑HT1F

5‑HT1B/1D

CNS Penetrant

Yes

No

Vasoconstrictor

No

Yes

 

The International Nonproprietary Name (INN) and United States Adopted Name (USAN) Committees have assigned a non-triptan generic stem name ("ditan") to lasmiditan based on its unique chemical structure, receptor selectivity, and mechanism of action.

 

Development Update

CoLucid has completed SAMURAI, the first of two pivotal Phase 3 clinical trials of lasmiditan oral tablets (see press release).

SPARTAN is a Phase 3 randomized, double-blind, placebo-controlled study being conducted under agreement with the FDA for a Special Protocol Assessment.  The trial is currently enrolling up to 2,226 patients with migraine, including those who have one or more CV risk factors, stable cardiovascular disease, or known coronary artery disease from approximately 140 sites in the U.S., United Kingdom and Germany. Top-line results are expected in mid-2017.

GLADIATOR is an open-label, long-term, safety study of lasmiditan in the acute treatment of migraine.  This trial is enrolling by invitation up to a total of 2,580 participants who have completed either of the SAMURAI and SPARTAN trials. Participants will be randomized to receive 100 mg or 200 mg of lasmiditan, and will be treated for up to eight migraine attacks per month for one year. 

 

Did You Know?

Did You Know?

That a Diagnosis for Migraine is a Risk Factor for Cardiovascular Disease? 

Learn More

CoLucid Pharmaceuticals Video Overview

CoLucid Pharmaceuticals Video Overview

Learn More

Percent of the Adult U.S. Population Affected

Percent of the Adult U.S. Population Affected

National Health Interview Survey, NCHS, 2014, CDC.gov April 2016

 
 

Learn About our Development Plan

Learn About our Development Plan

Learn More